Icon Advisers Increased Biotelemetry (BEAT) Holding by $887,403; Share Value Rose; Loudon Investment Management Lowered Its Position in Teva Pharmaceutical Inds LTD (TEVA) by $794,310

December 16, 2017 - By Nellie Frank

Icon Advisers Inc increased its stake in Biotelemetry Inc. (BEAT) by 31.13% based on its latest 2017Q2 regulatory filing with the SEC. Icon Advisers Inc bought 26,891 shares as the company’s stock rose 13.43% with the market. The institutional investor held 113,278 shares of the health care company at the end of 2017Q2, valued at $3.79M, up from 86,387 at the end of the previous reported quarter. Icon Advisers Inc who had been investing in Biotelemetry Inc. for a number of months, seems to be bullish on the $970.62 million market cap company. The stock increased 3.10% or $0.9 during the last trading session, reaching $29.95. About 1.22 million shares traded or 102.12% up from the average. BioTelemetry, Inc. (NASDAQ:BEAT) has risen 87.79% since December 16, 2016 and is uptrending. It has outperformed by 71.09% the S&P500.

Loudon Investment Management Llc decreased its stake in Teva Pharmaceutical Inds Ltd (TEVA) by 28.08% based on its latest 2017Q2 regulatory filing with the SEC. Loudon Investment Management Llc sold 24,070 shares as the company’s stock declined 15.11% while stock markets rallied. The institutional investor held 61,639 shares of the major pharmaceuticals company at the end of 2017Q2, valued at $2.05M, down from 85,709 at the end of the previous reported quarter. Loudon Investment Management Llc who had been investing in Teva Pharmaceutical Inds Ltd for a number of months, seems to be less bullish one the $18.91B market cap company. The stock increased 7.57% or $1.31 during the last trading session, reaching $18.61. About 66.14M shares traded or 157.39% up from the average. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 41.70% since December 16, 2016 and is downtrending. It has underperformed by 58.40% the S&P500.

Loudon Investment Management Llc, which manages about $170.56M and $131.72M US Long portfolio, upped its stake in Archer Daniels Midland Co (NYSE:ADM) by 16,010 shares to 40,706 shares, valued at $1.68 million in 2017Q2, according to the filing. It also increased its holding in V F Corp (NYSE:VFC) by 8,290 shares in the quarter, for a total of 48,631 shares, and has risen its stake in Anheuser Busch Inbev Sa/Nv (NYSE:BUD).

Among 32 analysts covering Teva Pharma (NYSE:TEVA), 8 have Buy rating, 5 Sell and 19 Hold. Therefore 25% are positive. Teva Pharma had 119 analyst reports since July 21, 2015 according to SRatingsIntel. On Wednesday, November 16 the stock rating was maintained by RBC Capital Markets with “Outperform”. Jefferies downgraded the stock to “Hold” rating in Wednesday, November 16 report. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Hold” rating given on Monday, February 13 by Maxim Group. Credit Suisse maintained the stock with “Underperform” rating in Monday, November 6 report. The stock has “Buy” rating by Oppenheimer on Friday, July 14. Maxim Group maintained the shares of TEVA in report on Thursday, July 13 with “Hold” rating. On Tuesday, November 7 the stock rating was downgraded by HSBC to “Reduce”. Mizuho maintained the stock with “Neutral” rating in Friday, November 17 report. On Wednesday, August 2 the stock rating was maintained by Mizuho with “Hold”. Oppenheimer maintained the shares of TEVA in report on Wednesday, October 4 with “Hold” rating.

Analysts await Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report earnings on February, 12. They expect $0.90 EPS, down 33.82% or $0.46 from last year’s $1.36 per share. TEVA’s profit will be $914.41M for 5.17 P/E if the $0.90 EPS becomes a reality. After $0.95 actual EPS reported by Teva Pharmaceutical Industries Limited for the previous quarter, Wall Street now forecasts -5.26% negative EPS growth.

Among 6 analysts covering BioTelemetry (NASDAQ:BEAT), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioTelemetry had 9 analyst reports since July 28, 2015 according to SRatingsIntel. The stock has “Buy” rating by Dougherty & Company on Tuesday, April 11. The stock has “Buy” rating by Raymond James on Thursday, November 30. The stock of BioTelemetry, Inc. (NASDAQ:BEAT) has “Buy” rating given on Friday, December 2 by Dougherty & Company. The stock of BioTelemetry, Inc. (NASDAQ:BEAT) has “Buy” rating given on Tuesday, July 28 by Dougherty & Company. Sidoti initiated the shares of BEAT in report on Tuesday, September 13 with “Buy” rating.

Investors sentiment decreased to 1.3 in Q2 2017. Its down 0.12, from 1.42 in 2017Q1. It dropped, as 18 investors sold BEAT shares while 58 reduced holdings. 41 funds opened positions while 58 raised stakes. 23.79 million shares or 8.10% more from 22.01 million shares in 2017Q1 were reported. Massachusetts Financial Ma stated it has 0% in BioTelemetry, Inc. (NASDAQ:BEAT). Castleark Mngmt Limited Liability Corp accumulated 352,947 shares. Perkins Cap Management holds 15,000 shares or 0.56% of its portfolio. Cannell Ltd holds 6.52% or 682,976 shares. State Common Retirement Fund holds 46,905 shares. Geode Management Ltd Liability Company holds 0% or 239,645 shares. Oppenheimer Asset Management has invested 0.01% in BioTelemetry, Inc. (NASDAQ:BEAT). Globeflex Ltd Partnership holds 1.02% in BioTelemetry, Inc. (NASDAQ:BEAT) or 123,747 shares. Susquehanna Intl Gp Llp has invested 0% in BioTelemetry, Inc. (NASDAQ:BEAT). Piermont Cap Mngmt stated it has 0.23% in BioTelemetry, Inc. (NASDAQ:BEAT). Millrace Asset has invested 0.67% in BioTelemetry, Inc. (NASDAQ:BEAT). Stifel Fincl holds 0.04% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT) for 321,385 shares. Manufacturers Life Insur Communication The reported 21,949 shares. Teachers Retirement Systems Of The State Of Kentucky, Kentucky-based fund reported 9,800 shares. Icon Advisers Inc Company owns 113,278 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: